tbuckley/cabot-search huggingface dataset:
Arginase is overactive in psoriatic skin
Authors: S. Abeyakirthi, M. Mowbray, N. Bredenkamp, L. Van Overloop, L. Declercq, P.J. Davis, M.S. Matsui, R.B. Weller
Journal: British Journal of Dermatology (2010)

Background Psoriatic keratinocytes are poorly differentiated and hyperproliferative. Low concentrations of nitric oxide (NO) induce keratinocyte proliferation, while high concentrations induce differentiation. The NO‐producing enzyme inducible NO synthase is overexpressed in psoriatic skin, but so is arginase. The overexpressed arginase competes for arginine, the common substrate for both enzymes, and may reduce NO production. Objectives To determine whether arginase activity is elevated in psoriatic skin and whether exogenous NO will improve psoriatic plaques. Methods Tape strips were taken from healthy skin of eight control subjects and nonlesional skin of eight patients with psoriasis and l‐arginine, l‐citrulline and l‐ornithine concentrations measured by high‐performance liquid chromatography. In a second study, four psoriatic patients with a pair of similar symmetrical plaques were treated with an NO donor and vehicle control. Plaques were scored for size, erythema, induration and scaling at the start and after 6 weeks of treatment. Results Ornithine, the end‐product of arginase, was at higher concentrations in nonlesional psoriatic than in healthy skin (mean ± SEM 2·08 ± 0·98 vs. 1·13 ± 0·44 μg mg−1 protein; P =0·0002). Arginine, its substrate, was at lower concentrations. Topical application of an NO donor improved psoriatic plaques clinically [mean ± SD reduction in severity from baseline score (100%) to 35% ± 16% in active NO donor and to 93% ± 10% in control]. Conclusions Arginase is overactive in psoriatic skin, leading to a relative increase in the consumption of arginine. We therefore hypothesize a relative decrease in NO synthase‐derived NO production. NO donors may be effective topical treatments for psoriasis.
Angiocardiography in Congenital Heart Malformations
Authors: Benigno Soto, Albert D. Pacifico
Journal: Annals of Internal Medicine (1991)

A study of angiography through cardiac morphology and cineangiographic technique. Compares actual morphology with angiographic translation for cardiac defects. Includes anomilies of the atria, the atrioventricular connection, the ventricles and the aorta. Also a section on the myocardium.
CTNNA3 and SEMA3D: Promising loci for asthma exacerbation identified through multiple genome-wide association studies
Authors: Michael J. McGeachie, Ann C. Wu, Sze Man Tse, George L. Clemmer, Joanne Sordillo, Blanca E. Himes, Jessica Lasky-Su, Robert P. Chase, Fernando D. Martinez, Peter Weeke, Christian M. Shaffer, Hua Xu, Josh C. Denny, Dan M. Roden, Reynold A. Panettieri, Benjamin A. Raby, Scott T. Weiss, Kelan G. Tantisira
Journal: Journal of Allergy and Clinical Immunology (2015)
Adherence to Teledermatology Recommendations by Primary Health Care Professionals
Authors: Iris Martin, Porntawee Paul Aphivantrakul, Kuang-Ho Chen, Suephy C. Chen
Journal: JAMA Dermatology (2015)

This review of teledermatology referral adherence reports that primary health care professionals followed 80% of recommendations and that physicians who attended a dermatology training course were no more likely to follow recommendations.
The Effect of Coenzyme Q<sub>10</sub> in Patients with Congestive Heart Failure
Authors: Meenakshi Khatta, Barbara S. Alexander, Cathy M. Krichten, Michael L. Fisher, Ronald Freudenberger, Shawn W. Robinson, Stephen S. Gottlieb
Journal: Annals of Internal Medicine (2000)

Background: Coenzyme Q10 is commonly used to treat congestive heart failure on the basis of data from several unblinded, subjective studies. Few randomized, blinded, controlled studies have evaluated objective measures of cardiac performance. Objective: To determine the effect of coenzyme Q10 on peak oxygen consumption, exercise duration, and ejection fraction. Design: Randomized, double-blind, controlled trial. Setting: University and Veterans Affairs hospitals. Patients: 55 patients who had congestive heart failure with New York Heart Association class III and IV symptoms, ejection fraction less than 40%, and peak oxygen consumption less than 17.0 mL/kg per minute (or <50% of predicted) during standard therapy were randomly assigned. Forty-six patients completed the study. Intervention: Coenzyme Q10, 200 mg/d, or placebo. Measurements: Left ventricular ejection fraction (measured by radionuclide ventriculography) and peak oxygen consumption and exercise duration (measured by a graded exercise evaluation using the Naughton protocol) with continuous metabolic monitoring. Results: Although the mean (±SD) serum concentration of coenzyme Q10 increased from 0.95 ± 0.62 µg/mL to 2.2 ± 1.2 µg/mL in patients who received active treatment, ejection fraction, peak oxygen consumption, and exercise duration remained unchanged in both the coenzyme Q10 and placebo groups. Conclusion: Coenzyme Q10 does not affect ejection fraction, peak oxygen consumption, or exercise duration in patients with congestive heart failure receiving standard medical therapy.
Southern Medical History
Authors: Jonathon Erlen
Journal: JAMA (2005)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Lung Function and Exercise Gas Exchange in Chronic Heart Failure
Authors: Bernard Aguilaniu, Eric Page, François Peronnet, Hélène Perrault
Journal: Circulation (1998)

Recently, Giannuzzi et al 1 eloquently described the beneficial effect of long-term exercise training on left ventricular remodeling in postinfarction patients.An earlier report from Coats et al 2 demonstrated that training can improve autonomic function (mainly in terms of RR variability and norepinephrine spillover) in patients with chronic heart failure but failed to show significant changes in resting catecholamine levels after a short-term exercise program.In an attempt to explain their findings, Giannuzzi et al used a series of reports describing the reduction of catecholamine levels by exercise training in subjects with normal left ventricular function 3,4 and speculated that this effect exists in patients with left ventricular dysfunction as well.However, this phenomenon is no longer conjectural because it has been demonstrated clearly in postinfarction patients with severe left ventricular dysfunction after long-term exercise rehabilitation. 5Moreover, that study 5 also showed a beneficial effect of the rehabilitation program on atrial natriuretic peptide.We hope that clarification of these points will provide additional support for the findings of Giannuzzi and his team.
Abstract 19285: Notch1 Haploinsufficiency Increases Risk of Congenital Heart Defects in the Setting of Maternal Diabetes by an Epigenetic Mechanism
Authors: Madhumita Basu, Kevin Bosse, Vidu Garg
Journal: Circulation (2014)

Congenital heart disease (CHD) is the most common type of birth defect. Epidemiologic studies have shown the importance of genetic and environmental factors in the multifactorial etiology of CHD. Maternal diabetes mellitus (DM) is one of the non-genetic risk factors that predisposes to CHD predominantly cardiac septation and cardiac outflow tract defects. DM is known to be associated with endothelial cell dysfunction and we recently demonstrated a genetic interaction between endothelial nitric oxide synthase and Notch1, which encodes a receptor that functions in an important cardiac developmental signaling pathway. We hypothesized that maternal DM in the setting of Notch1 heterozygosity of the developing embryo will predispose to CHD. Notch1 +/- embryos (E13.5) exposed to maternal DM demonstrated an increased incidence (86%) of ventricular septal defects compared to wildtype littermates (22%) (Table). Gene expression studies in non-diabetic wildtype, diabetic wildtype and Notch1 +/- embryos showed DM was associated with decreased Notch1 mRNA levels and upregulation in Jarid2, a histone H3K9 demethylase known to regulate Notch1. In H9C2 and endocardial-derived cells and chick embryos, we showed that hyperglycemia led to decreased expression of Notch1 and its downstream targets in a dose-dependent manner. Similarly, Jarid2 mRNA levels increased with high glucose. Furthermore, we found reduced luciferase reporter activity in cells transfected with a constitutively active Notch1 intracellular domain with hyperglycemia. Studies demonstrating the relative enrichment of Jarid2 on Notch1 locus with hyperglycemia by ChIP-qPCR will also be presented. Our findings reveal that maternal DM disrupts cardiac development by deregulating the Notch1 signaling pathway and suggest that this gene-environment interaction is mediated by an epigenetic mechanism involving Jarid2 providing the first mechanistic insights for this association.
Eruptive multiple sporadic cutaneous piloleiomyomas in a patient with chronic lymphocytic leukaemia
Authors: R. Vergani, R. Betti, L. Uziel, E. Tolomio, C. Crosti
Journal: British Journal of Dermatology (2000)

Journal Article Eruptive multiple sporadic cutaneous piloleiomyomas in a patient with chronic lymphocytic leukaemia Get access R. Vergani, R. Vergani Clinica Dermatologica IV and Search for other works by this author on: Oxford Academic Google Scholar R. Betti, R. Betti Clinica Dermatologica IV and Search for other works by this author on: Oxford Academic Google Scholar L. Uziel, L. Uziel Medicina I, Università degli Studi di Milano, Ospedale San Paolo, Via A. di Rudinì n° 8, 20142 Milano, Italy Correspondence: Dr Roberto BettiE‐mail: sdbet@tin.it Search for other works by this author on: Oxford Academic Google Scholar E. Tolomio, E. Tolomio Clinica Dermatologica IV and Search for other works by this author on: Oxford Academic Google Scholar C. Crosti C. Crosti Clinica Dermatologica IV and Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, Volume 143, Issue 4, 1 October 2000, Pages 907–909, https://doi.org/10.1046/j.1365-2133.2000.03806.x Published: 01 October 2000
LONGEVITY WITH METASTATIC CARCINOMA OF THE STOMACH
Authors: Steven O. Schwartz
Journal: Annals of Internal Medicine (1945)

Case Reports1 May 1945LONGEVITY WITH METASTATIC CARCINOMA OF THE STOMACHSTEVEN O. SCHWARTZ, M.D.STEVEN O. SCHWARTZ, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-22-5-727 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptThere is considerable evidence that carcinoma of the stomach may manifest itself as a disease of marked chronicity.1 Subsequent to metastases (especially to bones), however, the downward course is accepted to be relatively rapid. For this reason operative procedures for the alleviation of the primary lesion are undertaken with reluctance when metastases are demonstrable. A case is presented here with metastatic carcinoma demonstrated in the bone marrow three years before death, to reopen for question the validity of extreme surgical conservatism in the presence of metastases.CASE REPORTA 62 year old white male entered the Cook County Hospital on...Bibliography1. PALMER WL: The duration of gastric cancer, Gastroenterology, 1943, i, 723. Google Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Chicago, Illinois*Received for publication November 22, 1943.From the Hematological Laboratory, Cook County Hospital, Chicago, Illinois. Aided by a grant from the Wilson Laboratories. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byGastric Cancer: Diagnosis, Course, and Prognosis 1 May 1945Volume 22, Issue 5Page: 727-730KeywordsBoneBone marrowHematology and oncologyLesionsResearch laboratoriesStomachSurgery ePublished: 1 December 2008 Issue Published: 1 May 1945 PDF downloadLoading ...
Cardiopulmonary Exercise Testing Determination of Functional Capacity in Mitral Regurgitation
Authors: David Messika-Zeitoun, Bruce D. Johnson, Vuyisile Nkomo, Jean-François Avierinos, Thomas G. Allison, Christopher Scott, A. Jamil Tajik, Maurice Enriquez-Sarano
Journal: Journal of the American College of Cardiology (2006)
<i>Texas Windstorm</i>
Authors: Jeanette M. Smith
Journal: JAMA (2015)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The long pentraxin PTX3 binds to apoptotic cells and regulates their clearance by antigen-presenting dendritic cells
Authors: Patrizia Rovere, Giuseppe Peri, Fausto Fazzini, Barbara Bottazzi, Andrea Doni, Attilio Bondanza, Valérie S. Zimmermann, Cecilia Garlanda, Umberto Fascio, Maria Grazia Sabbadini, Claudio Rugarli, Alberto Mantovani, Angelo A. Manfredi
Journal: Blood (2000)
Collagen triple helix repeat containing-1 in the differential diagnosis of dermatofibrosarcoma protuberans and dermatofibroma
Authors: L. Wang, Y.N. Xiang, Y.H. Zhang, Y.T. Tu, H.X. Chen
Journal: British Journal of Dermatology (2010)

Background The distinction between dermatofibroma (DF) and dermatofibrosarcoma protuberans (DFSP) is a well-known challenge for dermatopathologists. Immunohistochemical stains have been used to augment routine histological examination to aid in differentiating DF from DFSP. Collagen triple helix repeat containing-1 (Cthrc1) was identified as a novel gene expressed in the adventitia and neointima on arterial injury. It is indicated to be a cell type-specific inhibitor of transforming growth factor-β, which in turn impacts collagen type I and III deposition, neointimal formation, and dedifferentiation of stem cells. Cthrc1 has also been shown to be highly active and potent in degrading extracellular matrix proteins and was found to be overexpressed in several malignant tumours, such as breast cancer and malignant melanoma. To our knowledge, however, expression of Cthrc1 in DFSP and DF has not been studied before. Objectives To assess the expression of Cthrc1 in DFSP and DF and to ascertain whether Cthrc1 is superior to antibodies traditionally used in differentiating DF from DFSP. Methods Immunohistochemical staining was performed on 23 cases of DFSP and 35 cases of DF, using antibodies to Cthrc1, CD34, factor XIIIa, CD10 and stromelysin-3 (ST3). Results Twenty-two of 23 (96%) DFSP samples were positive for Cthrc1, whereas 32 of 35 (91%) DF samples were negative. CD34 was expressed in most DFSPs (22 of 23, 96%), whereas it was completely negative in most cases of DF (29 of 35, 83%). Expression of factor XIIIa was found in most cases of DF (33 of 35, 94%), whereas it was completely absent in 21 of 23 (91%) DFSP cases. Expression of CD10 was found in most cases of DF (30 of 35, 86%), whereas it was completely absent in 13 of 23 (57%) DFSP cases. ST3 was expressed strongly in most cases of DF (32 of 35, 91%), whereas it was completely absent in 18 of 23 (78%) DFSP cases. The preferential Cthrc1 staining of DFSP in comparison with DF was statistically significant (P < 0·01). Conclusions We confirmed that Cthrc1 is a positive marker for DFSP and that Cthrc1 staining might be more reliable than markers traditionally used. Cthrc1 was not absolutely negative in all cases of DFSP, and combination with CD34, factor XIIIa and ST3 immunostaining could make the distinction more reliable.
939. Adenoviral-Mediated Neuronal-Specific Overexpression of the Angiotensin AT2 Receptor
Authors: Hongwei Li, Yongxin Gao, Mohan K. Raizada, Colin Sumners
Journal: Molecular Therapy (2004)

Top of pageAbstract
The angiotensin II type 2 receptor (AT2) is a G-protein coupled receptor that can influence a variety of intracellular signaling molecules and cellular functions. The AT2 is highly expressed in neonatal brain and regulates several functions of nerve cells, e.g., ionic fluxes, cell differentiation, axonal regeneration and programmed cell death. However, the physiological roles of the AT2 receptor remain poorly defined. Adenoviral vectors are amongst the most efficient vectors for gene transfer, and have been used to transduce both neurons and non-neuronal cells (astroglia, oligodendroglia, microglia, and endothelial cells) in vitro and in vivo. However, glia are transduced with higher efficiency than neurons. This means that in primary neuronal cultures (which usually contain a small percentage of glia) and in brain in vivo the majority of transgene is expressed in the non-neuronal cells. Therefore, in order to study the functions of AT2 in neurons, and target AT2 expression solely to these cells, we developed a recombinant adenoviral vector Ad5-SYN-AT2-IRES-GFP containing both the AT2 gene and an IRES-linked GFP reporter gene, driven by the synapsin 1 (SYN) gene promoter. Primary cortical neuronal cultures, which contain low or undetectable levels of AT2, were transfected with the recombinant Ad5-SYN-AT2-IRES-GFP. Immunocytochemistry, 125SI-AngII receptor binding and real-time RT-PCR were used to identify the expression of AT2 or GFP. The results showed that the high level expression of both AT2 and GFP was restricted exclusively to neurons and that no AT2 over-expression was detected in glial cells. Thus, this vector provides a highly effective means of directing AT2-specific expression in neurons, and as such is an important tool for investigations of its function in the brain and in gene therapy studies involving AT2 receptors in neurons.
Effect of pulmonary-specific vasodilator therapy in patients with chronic obstructive pulmonary disease and pulmonary hypertension. A retrospective analysis
Authors: Laura Fossati, Séverine Müller-Mottet, Elisabeth Hasler, Lars C. Huber, Rudolf Speich, Konrad E. Bloch, Silvia Ulrich
Journal: European Respiratory Journal (2014)

Background : Severe pulmonary hypertension (PH) due to COPD has dismal prognosis. PH-target-therapy may worsen ventilation-perfusion mismatch and is insufficiently studied.

Method : For COPD-PH-patients, PH-target-therapy, NYHA, 6MWD, SpO2 and QoL were noted at baseline,3,6,12&24 months.

Results : Data from 27 patients were analysed (7 females, 21 smokers, 23 emphysema) baseline median(quartiles):age 70(60;76), FEV1 60(46;78)%, FEV1/FVC 57(51;64)%, DLCO 42(36;59)%, mPAP 39(32;44)mmHg. Therapies included inhaled-iloprost(10), sc-treprostinil(2), iv-prostanoids(3), endothelin-receptor antagonists(15) and PDE-5-inhibitors(25). Under therapy, NYHA improved from 3.5(3;4) to 3(2;4) and 3(2;3.5) at 3&6 months (p= 0.02&0.008), the 6MWD from 373(236;452) to 395(339;472), 414(285;492)& 396(308;497)m at 3,6&12 months(p= 0.005,0.006&0.011) with unchanged resting-SpO2 of 92(86;94)% but decreased SpO2 after 6MW to 87(79;92) to 81(76;87), 83(76;88)& 80(82;89)% (p=0.014, 0.014&0.116). During median follow-up of 5.9(2.3;8.4)years, 10 died (after 3.1(2.3;4.3)years, 2 were transplanted (after 2.7(1.7;3.6)years) and 2 lost-to-follow-up after 3.3(2.2;4.4)years. Transplant-free-survival at 1,2,3 years was 92,69 and 54% and was similar for GOLD-stages 1-4, but worse for patients with mPAP≥40mmHg (p= 0.026), 6MWD<370m (p= 0.008), resting SpO2<92% (p= 0.02) and post-walk SpO2<87% (p= 0.012).

Conclusion : PH-target-therapy improved NYHA and 6MWD in selected COPD patients with severe PH with worsening resting SpO2. Poor exercise capacity, low SpO2 and high mPAP but not airflow obstruction were associated with unfavourable outcome.
Voriconazole‐induced periostitis after allogeneic stem cell transplantation
Authors: John H. Baird, Belinda K. Birnbaum, David L. Porter, Noelle V. Frey
Journal: American Journal of Hematology (2015)

A 64-year-old man with a history of resected renal cell carcinoma and acute myelogenous leukemia in first remission, presented 3 months after a non-myeloablative, human leukocyte antigen (HLA) -matched sibling allogeneic stem cell transplantation with diffuse, migratory arthralgias, and myalgias. Joint effusions were noted on examination, and diagnostic arthrocenteses of both knees demonstrated an inflammatory arthritis without evidence of infection or crystals. The polyarthritis and myalgias were poorly responsive to an extended course of systemic corticosteroids. Bone scintigraphy performed with the use of technetium-99m-labeled medronic acid demonstrated multiple osteoblastic lesions in the axial skeleton (Image 1, Panel A ), consistent with periostitis or bony exostoses. Among other medications, the patient had been on 400 mg of voriconazole daily for 4 months to treat a fungal pneumonia which developed during induction chemotherapy. The patient's voriconazole was changed to caspofungin, and within 4 days his symptoms resolved completely. A repeat bone scintigraphy scan obtained 2 months later revealed complete resolution of the osteoblastic lesions (Image 1, Panel B). Voriconazole-associated periostitis and osteoblastic skeletal disease have been reported in the literature in solid organ and hematopoietic stem cell transplant recipients receiving long-term suppressive antifungal therapy, and is usually associated with elevated serum fluoride levels thought to be integral to the disease's pathogenesis 1-4. Our case highlights the importance of including medication-induced periostitis in the differential diagnosis of arthralgias and bone pain following allogeneic stem cell transplantation, and highlights the utility of bone scintography in establishing the diagnosis and monitoring response upon withdrawal of offending medications. Whole body bone scintigraphy utilizing Tc-99m MDA radiotracer. Panel A: prior to voriconazole discontinuation, demonstrates multiple areas of increased radiotracer uptake consistent with osteoblastic lesions throughout the axial and appendicular skeleton (arrows). Panel B: 2 months following voriconazole discontinuation, shows physiologic radiotracer distribution with no evidence of the previously noted lesions. Of note, the patient previously had a right nephrectomy for removal of a renal cell carcinoma, thus explaining the absence of its shadow on the posterior scintigraphs.